Key Points
- VP David Foehr sold 5,556 shares of CeriBell on Jan. 5 at an average price of $22.60 for $125,565.60, leaving him with 18,900 shares (a 22.72% reduction); he also sold 5,265 shares on Dec. 3 at $16.83.
- CeriBell shares opened at $22.83 (up ~5.1%), the company has a market cap of about $847M and reported a beat on the last quarter (EPS -$0.37 vs. -$0.43; revenue $22.59M), but remains unprofitable with analysts projecting roughly -2.46 EPS for the year.
- Analyst sentiment is broadly positive with an average rating of "Moderate Buy" (one Strong Buy, six Buy, one Sell) and an average price target of $24.67, though individual targets range from $19–$30.
CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) VP David Foehr sold 5,556 shares of the firm's stock in a transaction on Monday, January 5th. The shares were sold at an average price of $22.60, for a total value of $125,565.60. Following the completion of the transaction, the vice president owned 18,900 shares in the company, valued at $427,140. The trade was a 22.72% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
David Foehr also recently made the following trade(s):
- On Wednesday, December 3rd, David Foehr sold 5,265 shares of CeriBell stock. The stock was sold at an average price of $16.83, for a total transaction of $88,609.95.
CeriBell Stock Up 5.1%
Shares of NASDAQ CBLL opened at $22.83 on Thursday. The stock has a market cap of $846.99 million, a PE ratio of -15.12 and a beta of 1.02. The company has a current ratio of 12.65, a quick ratio of 12.25 and a debt-to-equity ratio of 0.12. CeriBell, Inc. has a 12-month low of $10.01 and a 12-month high of $26.04. The company has a 50-day moving average of $17.54 and a 200 day moving average of $15.03.
CeriBell (NASDAQ:CBLL - Get Free Report) last issued its earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.06. The business had revenue of $22.59 million for the quarter, compared to analysts' expectations of $21.78 million. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%. As a group, sell-side analysts predict that CeriBell, Inc. will post -2.46 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of brokerages have issued reports on CBLL. Raymond James Financial initiated coverage on CeriBell in a research note on Tuesday, October 21st. They issued a "strong-buy" rating and a $19.00 target price for the company. Weiss Ratings restated a "sell (e+)" rating on shares of CeriBell in a research report on Wednesday, October 8th. TD Cowen reduced their target price on shares of CeriBell from $36.00 to $20.00 and set a "buy" rating on the stock in a research note on Wednesday, November 5th. Canaccord Genuity Group raised their price target on shares of CeriBell from $29.00 to $30.00 and gave the stock a "buy" rating in a report on Wednesday, December 17th. Finally, BTIG Research reiterated a "buy" rating and issued a $30.00 price objective on shares of CeriBell in a report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $24.67.
Get Our Latest Stock Analysis on CeriBell
Institutional Investors Weigh In On CeriBell
A number of institutional investors have recently made changes to their positions in CBLL. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of CeriBell in the 3rd quarter valued at approximately $33,000. Tower Research Capital LLC TRC boosted its position in shares of CeriBell by 353.8% during the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company's stock worth $43,000 after buying an additional 1,801 shares during the period. Ameritas Investment Partners Inc. raised its holdings in shares of CeriBell by 97.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company's stock valued at $48,000 after buying an additional 1,256 shares during the period. Police & Firemen s Retirement System of New Jersey boosted its holdings in CeriBell by 161.0% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company's stock valued at $106,000 after acquiring an additional 3,502 shares during the period. Finally, Sherbrooke Park Advisers LLC acquired a new stake in shares of CeriBell during the third quarter worth about $135,000.
CeriBell Company Profile
(
Get Free Report)
CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell's solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.
The company's product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
